NRx Pharmaceuticals Refiles FDA Application for KetaFree | $3.3B Ketamine Market
Biotech investors and healthcare innovators: NRx Pharmaceuticals has refiled its ANDA with the FDA for KetaFree™, its preservative-free IV ketamine formulation.
📌 Key Highlights:
Targets all approved ketamine indications
Backed by FDA approval of suitability petition for proposed strength
Current ketamine market: $750M, projected $3.3B by 2034
KetaFree™ distinct from NRx’s NRX-100, which is in trials for suicidal ideation in depression (Fast Track designated)
This filing advances NRx’s mission to deliver safe, innovative ketamine therapies across multiple indications.
🔖 YouTube Tags:
#NRxPharmaceuticals #KetaFree #KetamineTherapy #FDAApproval #ANDA #NRX100 #SuicidalIdeation #DepressionTreatment #BipolarDepression #BiotechInvesting #DrugDevelopment #HealthcareInnovation #NewsOut #JaneKing
